DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)
China flag China · Delayed Price · Currency is CNY
20.71
-0.11 (-0.53%)
Nov 18, 2026, 3:00 PM CST

SHA:603233 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
28,08526,84525,86123,93120,78016,759
Other Revenue
657.1657.1635.56599.94467.67-
28,74227,50226,49724,53121,24816,759
Revenue Growth
7.11%3.79%8.01%15.45%26.78%14.92%
Cost of Revenue
18,86818,09217,42215,79513,22610,385
Gross Profit
9,8749,4109,0748,7368,0226,374
Selling, General & Admin
7,3637,2157,4246,8086,2705,187
Research & Development
23.3541.2751.6880.9374.3844.61
Other Operating Expenses
143.93105.2335.4735.3264.5729.94
Operating Expenses
7,5467,3757,5276,9406,4325,273
Operating Income
2,3292,0361,5471,7961,5901,101
Interest Expense
-155.83-189.38-248.83-239.26-231.97-212.04
Interest & Investment Income
62.1569.682.2391.7568.8977.7
Currency Exchange Gain (Loss)
-0.7-0.70.32---
Other Non Operating Income (Expenses)
-78.83-34.45-46.64-49.85-48.52-29.15
EBT Excluding Unusual Items
2,1551,8811,3351,5991,379937.76
Impairment of Goodwill
-53.58-53.58-38.6-6.21--
Gain (Loss) on Sale of Investments
-15.01-1.5210.614.38-18.7134.57
Gain (Loss) on Sale of Assets
17.4414.719.213.4318.735.63
Asset Writedown
9.96-----
Other Unusual Items
9.19.113.8927.0536.3665.94
Pretax Income
2,1231,8491,3401,6281,4151,044
Income Tax Expense
556.03490.53359.73397.12335.62239.52
Earnings From Continuing Operations
1,5671,359979.941,2311,079804.39
Minority Interest in Earnings
-142.13-123.67-65.19-64.16-43.55-13.16
Net Income
1,4251,235914.751,1661,036791.23
Net Income to Common
1,4251,235914.751,1661,036791.23
Net Income Growth
25.27%35.04%-21.58%12.63%30.90%-25.51%
Shares Outstanding (Basic)
1,1411,1441,1291,1331,1381,130
Shares Outstanding (Diluted)
1,1411,1441,1291,1331,1381,130
Shares Change
1.49%1.28%-0.28%-0.50%0.69%-0.24%
EPS (Basic)
1.251.080.811.030.910.70
EPS (Diluted)
1.251.080.811.030.910.70
EPS Growth
23.43%33.33%-21.36%13.19%30.00%-25.33%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
3,2504,8651,6261,3772,722260.05
Free Cash Flow Per Share
2.854.251.441.222.390.23
Dividend Per Share
0.9000.8300.6200.3100.5000.347
Dividend Growth
38.46%33.87%100.00%-38.00%43.97%-24.99%
Gross Margin
34.35%34.22%34.25%35.61%37.76%38.03%
Operating Margin
8.10%7.40%5.84%7.32%7.48%6.57%
Profit Margin
4.96%4.49%3.45%4.75%4.87%4.72%
Free Cash Flow Margin
11.31%17.69%6.14%5.61%12.81%1.55%
EBITDA
2,5882,3021,8243,2441,8081,306
EBITDA Margin
9.00%8.37%6.88%13.22%8.51%7.79%
D&A For EBITDA
259.09266.52276.411,448218.06204.62
EBIT
2,3292,0361,5471,7961,5901,101
EBIT Margin
8.10%7.40%5.84%7.32%7.48%6.57%
Effective Tax Rate
26.19%26.52%26.85%24.40%23.72%22.94%
Revenue as Reported
28,74227,50226,49724,53121,24816,759
Advertising Expenses
--25.4930.8126.27-